Compounds receptors ligands of gastrin and cholecystokinin (CCK), Pharmaceutical Composition and uses

摘要

1. Claim 1: use of a formula compound (1),Among them, R1 and R5 are independent h, C1-6 (C1-6 tar) oxy, uncle (C1-6 tar) uncle, anthrax, anthrax (C1-6 tar),1. Carbonate (C1-6 tar), carbon (C1-6 tar), oxygen carbonate (C1-6 tar), carbonate, nitric acid, trihalomethyl, hydroxy, hydroxy (C1-6 tar);1. Amino (C1-6 tar) amino, di (C1-6 tar) amine, amine, aminano, carbonilo, halo, halo (hydrocarbon 1-6),aminosulfonyl, (C1-6alkyl) sulfonylamino, (C1-6alkyl) aminocarbonyl, di (C1-6alkyl) aminocarbonyl, [NZ] - (C1-6alkyl) carbonylamino, formyloxy, formed, (C1-6alkyl) aminosulfonyl, di (C1-6 alkyl) aminosulfonyl, [NZ] - (C1-6 alkyl) sulfonylamino or cyano; or R1 and R5 together form a methylenedioxy group; R2 is an optionally substituted C1-18 hydrocarbyl group wherein up to three C atoms can optionally be replaced by N, O and / or S atoms; R3 is - (CR11R12) m-X- (CR13R14) p-R9; m is 0, 1 or 2; p is 0, 1 or 2; X is a bond, -CR15 = CR16-,-CSC...This is life. This is life.I am me, I am me.C (O) O, NHC (O) NH, NHC (O) O, OC (O) NH, NH, O, CO, SO2, SO2NH, C (O) NHNH, or is a residue selected from the group of formula ( two);R9 is No. h, C1-6 tar; or phenyl, nafilo, pyridilol, benzimidazolello, indazollo, quinol Nile, isoginolinello, tetrahydroisomer benzene, indolillo, isoindia Lillo or 2-pyridonia, all of which are independently selected from: - L-Q by groups 1, 2, or 3, of which l is the contact person, Or a set of formulas - (cr17r18) v-y-cr17r18) W, where V and W are independent of 0, 1, 2 or 3, e is a link, - Cr15 = cr16 -.thiazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, isoxazolonyl, piperazinyl, piperidinyl, morpholinyl, or pyrrolidinyl; and Q is H; (C1-6alkyl) oxy, [NZ] - (C1-6alkyl) oxy (C1-6alkyl) amino, thio, (C1-6alkyl) thio, carboxy (C1-6alkyl) thio, carboxy, carboxy ( C1-6alkyl),carboxi (alquenilo C1-6)Carcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcarcar8 [N-Z] (C1-6 tar) carbonate (tar 1-6 amine, halo, halo (C1-6 tar),sulfamoyl, [NZ] (C1-6 alkyl) sulfonylamino, (C1-6 alkyl) sulfonylaminocarbonyl, carboxy (C1-6 alkyl) sulfonyl, carboxy (C1-6 alkyl) sulfinyl, tetrazolyl, [NZ] tetrazolylamino, cyano, amidino, amidinothio , SO3H, formyloxy, formamido, C3-8 cycloalkyl, (C1-6 alkyl) -sulfamoyl, di (C1-6 alkyl) sulfamoyl, (C1-6 alkyl) -carbonylaminosulfonyl or 5-oxo-2,5-dihydro- [ 1,2,4] oxadiazolyl; Z is H, C1-6 alkyl, t-butoxycarbonyl, acetyl, benzoyl, or benzyl; R4 is an optionally substituted C1-18 hydrocarbyl group wherein up to three C atoms can optionally be replaced by N, O and / or S atoms; and R11, R12, R13, R14, R15, R16,R17 and R18 are independent h or c1-3 bitumens or their pharmaceutically acceptable salts that can be used in the treatment of gastrointestinal diseases. Claim 18: an ingredient in accordance with claim 16 or 17, with a proton pump inhibitor and a formula compound (1) each accounting for one quantity, has a beneficial therapeutic effect on patients with gastrointestinal diseases.